Literature DB >> 35834270

Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.

Fei Chen1, Sungshim L Park2, Lynne R Wilkens2, Peggy Wan1, Steven N Hart3, Chunling Hu4, Siddhartha Yadav5, Fergus J Couch3,4, David V Conti1, Adam J de Smith1, Christopher A Haiman1.   

Abstract

Women who have had breast cancer in the past are at increased risk of developing a second primary cancer (SPC), including second primary breast cancer (SPBC) or a second primary non-breast cancer (SPNBC). In the Multiethnic Cohort (MEC) Study, we conducted a prospective cohort analysis in 3,223 female breast cancer survivors from five racial/ethnic populations (White, African American, Japanese American, Latino, and Native Hawaiian) to assess the association of rare pathogenic variants (PV) in 37 known cancer predisposition genes with risk of SPC. A total of 719 (22.3%) women developed SPC, of which, 323 (10.0%) were SPBC. Germline PVs in BRCA1 (HR, 2.28; 95% CI, 1.11-4.65) and ERCC2 (HR, 3.51; 95% CI, 1.29-9.54) were significantly enriched in women with SPC. In the subtype analysis for SPBC, a significant association of ERCC2 PVs (HR, 5.09; 95% CI, 1.58-16.4) and a suggestive association of BRCA2 PVs (HR, 2.24; 95% CI, 0.91-5.55) were observed. There was also a higher risk of SPNBC in carriers of BRCA1 PVs (HR, 2.98; 95% CI, 1.21-7.36). These results provide evidence that germline PVs in BRCA1, BRCA2, and ERCC2 contribute to the development of SPC in breast cancer survivors. These findings also suggest that compromised DNA repair mechanisms could be a predisposition factor for SPC in patients with breast cancer, supporting the need for closer monitoring of SPC in women carrying PVs in these genes. SIGNIFICANCE: This multiethnic study links germline pathogenic variants in BRCA1, BRCA2, and ERCC2 to the development of second primary cancer in breast cancer survivors, providing biological insights and biomarkers to guide patient monitoring. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35834270      PMCID: PMC9481694          DOI: 10.1158/0008-5472.CAN-21-4461

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  44 in total

Review 1.  Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients.

Authors:  Trine Grantzau; Jens Overgaard
Journal:  Radiother Oncol       Date:  2016-09-14       Impact factor: 6.280

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.

Authors:  Tehillah S Menes; Mary Beth Terry; David Goldgar; Irene L Andrulis; Julia A Knight; Esther M John; Yuyan Liao; Melissa Southey; Alexander Miron; Wendy Chung; Saundra S Buys
Journal:  Breast Cancer Res Treat       Date:  2015-05-15       Impact factor: 4.872

4.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

5.  XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer.

Authors:  Abenaa M Brewster; Anthony J Alberg; Paul T Strickland; Sandy C Hoffman; Kathy Helzlsouer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-08       Impact factor: 4.254

6.  Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.

Authors:  Lisbeth Bertelsen; Leslie Bernstein; Jørgen H Olsen; Lene Mellemkjaer; Robert W Haile; Charles F Lynch; Kathleen E Malone; Hoda Anton-Culver; Jane Christensen; Bryan Langholz; Duncan C Thomas; Colin B Begg; Marinela Capanu; Bent Ejlertsen; Marilyn Stovall; John D Boice; Roy E Shore; Jonine L Bernstein
Journal:  J Natl Cancer Inst       Date:  2007-12-25       Impact factor: 13.506

7.  Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.

Authors:  Sara J Schonfeld; Lindsay M Morton; Amy Berrington de González; Rochelle E Curtis; Cari M Kitahara
Journal:  Cancer Epidemiol       Date:  2019-12-26       Impact factor: 2.984

8.  Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk.

Authors:  Jiali Han; Christopher Haiman; Tianhua Niu; Qun Guo; David G Cox; Walter C Willett; Susan E Hankinson; David J Hunter
Journal:  Breast Cancer Res Treat       Date:  2008-06-13       Impact factor: 4.872

9.  Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data.

Authors:  Zhenchong Xiong; Lin Yang; Guangzheng Deng; Xinjian Huang; Xing Li; Xinhua Xie; Jin Wang; Zeyu Shuang; Xi Wang
Journal:  J Clin Med       Date:  2018-05-31       Impact factor: 4.241

10.  Contribution of xeroderma pigmentosum complementation group D gene polymorphisms in breast and ovarian cancer susceptibility: A protocol for systematic review and meta analysis.

Authors:  Yumei Tian; Xiaojuan Lin; Fan Yang; Jitong Zhao; Kui Yao; Ce Bian
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.